06.12.2012 - The Innovative Medicines Initiative funds seven new projects with a total of €237m. The main focus is on drug development and data integration.
The exciting field of stem cell research and the seemingly insurmountable ranges of biodata are undergoing in-depth analyses over the next few years. The unifying context behind these projects is the mission to improve drug development. As announced on 5 December, the Innovative Medicines Alliance (IMI) will spend in total more than €237m on research topics ranging from stem cells (STEMBANCC), data integration (EMIF and eTRIKS) and ‚green’ drug development (CHEM21) to drug-target-interaction (K4DD), drug uptake into (ORBITO) and drug distribution within (COMPACT) the body.
Within STEMBANCC ten pharmaceutical companies and 23 academic institutions from 11 countries will develop 1,500 human induced pluripotent stem cell lines from about 500 patients to study diseases and test drugs for safety and efficacy. Swiss pharma Roche initiated the project, which will be coordinated by the University of Oxford (UK). Using cells isolated from patients, the scientists hope to identify the genes and mechanisms that play a role in diseases of the nervous system such as peripheral pain, migraine, autism, schizophrenia, bipolar disorders, dementiae and diabetes. Taken together, IMI now finances 37 projects with a volume of almost €800m.
It was just in June this year, that the last current IMI projects were presented. The €215m they received is only 91% of the sum the new projects of the 4th wave will get. The IMI, a joint venture of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) is Europe’s biggest public-private partnership to accelerate the development of better drugs. Currently, applicants can bid for the 8th call „Combating Antibiotic Resistance“. The calls five to seven have already been closed for submission of Expressions of Interest (EoI) and are in different stages of processing.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.